- Home
- MRNA vs COR Comparison
MRNA vs COR Comparison
Compare MRNA & COR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | COR |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 59.0B |
| IPO Year | 2018 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MRNA | COR |
|---|---|---|
| Price | $154.25 | $310.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 14 |
| Target Price | $34.27 | ★ $390.62 |
| AVG Volume (30 Days) | ★ 23.7M | 1.0M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.77% |
| EPS Growth | ★ 21.77 | 5.71 |
| EPS | N/A | ★ 15.21 |
| Revenue | $19,263,000,000.00 | ★ $321,332,819,000.00 |
| Revenue This Year | $9.36 | $8.89 |
| Revenue Next Year | $15.43 | $6.75 |
| P/E Ratio | ★ N/A | $20.34 |
| Revenue Growth | 4.29 | ★ 9.31 |
| 52 Week Low | $22.28 | $244.82 |
| 52 Week High | $176.66 | $377.54 |
Technical Indicators
Market Signals| Indicator | MRNA | COR |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 40.89 |
| Support Level | $46.85 | $308.48 |
| Resistance Level | $156.42 | $312.18 |
| Average True Range (ATR) | 9.54 | 6.59 |
| MACD | -1.67 | -2.57 |
| Stochastic Oscillator | 78.72 | 17.75 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About COR Cencora Inc.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.